Long-Term Evidence On Artificial Cervical Discs Found Lacking By Blues' TEC
This article was originally published in The Gray Sheet
Executive Summary
Long-term data is insufficient to show whether artificial intervertebral disc arthroplasty improves outcomes in the cervical spine, according to a recent assessment by the Blue Cross Blue Shield Association Technology Evaluation Center
You may also be interested in...
Research Briefs: Esophageal Stent Removal; Pill-Sized Pacer; Spinal-Stim Pain Relief; Prestige
Cook studies removability of esophageal covered stent. Medtronic evaluates pill-sized pacemaker. More research news.
Research In Brief
CT angiography: Computerized tomographic angiography (CTA) is a safe and effective diagnostic method for ruling out serious cardiovascular disease in patients who come to an emergency department with chest pains, according to the lead author of a long-term study of CTA screening presented May 15 at the Society for Academic Emergency Medicine's annual conference in New Orleans. In the study, led by Judd Hollander, University of Pennsylvania, 481 patients who had no evidence of coronary blockage in a CTA scan were followed for one year. None of the patients had a heart attack or required a coronary revascularization procedure during the follow-up, although 11% were rehospitalized for further cardiac testing. "The ability to rapidly determine that there is nothing seriously wrong allows us to provide reassurance to the patient and to help reduce crowding in the emergency department," Hollander said. According to the Medical Imaging & Technology Alliance, previous research has shown that CTA screening saves $2,500 per patient versus admitting the patient to the hospital for more extensive testing. In a MITA press release, Hollander says: "The evidence now clearly shows that when used in appropriate patients in the emergency department, we can safely and rapidly reduce hospital admission and save money.
With Medicare Coverage Policy Pending, Blue Cross Finds Fault With ProDisc
A recent negative assessment of lumbar artificial disc replacement by Blue Cross Blue Shield could spell trouble for Synthes as it seeks full Medicare coverage for ProDisc